We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

795 hedge funds and large institutions have $26B invested in Teva Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 69 funds opening new positions, 268 increasing their positions, 324 reducing their positions, and 75 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less call options, than puts

Call options by funds: $595M | Put options by funds: $620M

8% less first-time investments, than exits

New positions opened: 69 | Existing positions closed: 75

2% less funds holding

Funds holding: 812 → 795 (-17)

2.34% less ownership

Funds ownership: 58.38% → 56.04% (-2.3%)

13% less capital invested

Capital invested by funds: $30B → $26B (-$3.92B)

15% less funds holding in top 10

Funds holding in top 10: 41 → 35 (-6)

17% less repeat investments, than reductions

Existing positions increased: 268 | Existing positions reduced: 324

Holders
795
Holders Change
-17
Holders Change %
-2.09%
% of All Funds
21.21%
Holding in Top 10
35
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-14.63%
% of All Funds
0.93%
New
69
Increased
268
Reduced
324
Closed
75
Calls
$595M
Puts
$620M
Net Calls
-$24.3M
Net Calls Change
-$252M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$310M
2
Franklin Resources
Franklin Resources
California
+$295M
3
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss
Texas
+$202M
4
Capital Research Global Investors
Capital Research Global Investors
California
+$188M
5
JP Morgan Chase
JP Morgan Chase
New York
+$179M

Top Sellers

1
Viking Global Investors
Viking Global Investors
Connecticut
-$420M
2
PC
PointState Capital
New York
-$309M
3
HCM
Highfields Capital Management
Massachusetts
-$280M
4
IC
Institutional Capital
Illinois
-$217M
5
MIFH
Migdal Insurance & Financial Holdings
Israel
-$193M
Name Holding Trade Value Shares
Change 		Change in
Stake
FIM
351
Freedom Investment Management
Connecticut
$1.8M +$315K +6,047 +18%
JPC
352
Jackson Park Capital
Utah
$1.79M – – –
HIC
353
Hartline Investment Corp
Illinois
$1.78M -$2.04K -39 -0.1%
EB
354
Eastern Bank
Massachusetts
$1.75M -$49.4K -947 -2%
BWM
355
Braver Wealth Management
Massachusetts
$1.74M +$1.97M +37,770 New
GA
356
GFS Advisors
Texas
$1.73M +$814K +15,600 +71%
ACM
357
Argyle Capital Management
Pennsylvania
$1.73M +$2.61K +50 +0.1%
SB
358
Simmons Bank
Arkansas
$1.7M -$119K -2,272 -6%
Verition Fund Management
359
Verition Fund Management
Connecticut
$1.7M +$388K +7,445 +25%
SAM
360
Smithbridge Asset Management
Pennsylvania
$1.69M – – –
1832 Asset Management
361
1832 Asset Management
Ontario, Canada
$1.68M -$165K -3,166 -8%
ECM
362
ETrade Capital Management
Virginia
$1.67M +$98.8K +1,894 +6%
CI
363
Cowen Inc
New York
$1.66M +$1.89M +36,165 New
PGA
364
Portland Global Advisors
Maine
$1.65M -$1.56K -30 -0.1%
SFFS
365
Stonehage Fleming Financial Services
Jersey
$1.64M +$263K +5,050 +17%
CIP
366
Cornerstone Investment Partners
Georgia
$1.63M +$2.71K +52 +0.1%
LTFS
367
Ladenburg Thalmann Financial Services
Florida
$1.61M +$142K +2,731 +8%
SCM
368
SOL Capital Management
Maryland
$1.58M +$99.1K +1,900 +6%
EAM
369
EULAV Asset Management
Florida
$1.57M – – –
FAAS
370
First Allied Advisory Services
California
$1.54M +$26.5K +507 +2%
EI
371
EDMP Inc
Florida
$1.53M -$78.2K -1,498 -4%
ACM
372
Americafirst Capital Management
California
$1.51M +$1.71M +32,767 New
CB
373
Chemical Bank
Michigan
$1.5M +$289K +5,547 +21%
ID
374
Integral Derivatives
New York
$1.5M +$616K +11,804 +57%
DC
375
Davenport & Co
Virginia
$1.5M -$34.7K -666 -2%
13 14
15
16 17

TEVA Hedge Fund Activity: Q3 2016 in Review

795 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2016, worth a combined $26B — down 13% from $30B a quarter earlier.

Sellers outnumbered buyers: 75 funds closed out of TEVA and 69 opened new positions — a net loss of 6 holders — while 324 trimmed existing stakes and 268 added.

The largest buyer was Morgan Stanley, adding an estimated $310M. The largest seller was Viking Global Investors, cutting an estimated $420M.

  • 795 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2016, down from 812 in Q2 2016.
  • Funds reported $26B of Teva Pharmaceuticals stock for Q3 2016, down 13% quarter-over-quarter.
  • 69 funds opened new Teva Pharmaceuticals positions in Q3 2016 and 75 closed out, a net change of -6 holders.
  • The largest Teva Pharmaceuticals buyer in Q3 2016 was Morgan Stanley, an estimated $310M added.
  • The largest Teva Pharmaceuticals seller in Q3 2016 was Viking Global Investors, an estimated $420M sold.

Based on aggregated 13F filings for Q3 2016.